These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 29352843

  • 1. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.
    Iannazzo S, Benucci M, Favalli EG.
    Clin Exp Rheumatol; 2018; 36(3):479-485. PubMed ID: 29352843
    [Abstract] [Full Text] [Related]

  • 2. Cost-effectiveness of sequenced treatment of rheumatoid arthritis with targeted immune modulators.
    Jansen JP, Incerti D, Mutebi A, Peneva D, MacEwan JP, Stolshek B, Kaur P, Gharaibeh M, Strand V.
    J Med Econ; 2017 Jul; 20(7):703-714. PubMed ID: 28294642
    [Abstract] [Full Text] [Related]

  • 3. Cost-utility analysis of certolizumab pegol in combination with methotrexate in patients with moderate-to-severe active rheumatoid arthritis in Greece.
    Tzanetakos C, Tzioufas A, Goules A, Kourlaba G, Theodoratou T, Christou P, Maniadakis N.
    Rheumatol Int; 2017 Sep; 37(9):1441-1452. PubMed ID: 28523420
    [Abstract] [Full Text] [Related]

  • 4. Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
    Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W.
    Adv Ther; 2017 Nov; 34(11):2422-2435. PubMed ID: 29039054
    [Abstract] [Full Text] [Related]

  • 5. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach.
    Cimmino MA, Leardini G, Salaffi F, Intorcia M, Bellatreccia A, Dupont D, Beresniak A.
    Clin Exp Rheumatol; 2011 Nov; 29(4):633-41. PubMed ID: 21813056
    [Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
    Beresniak A, Baerwald C, Zeidler H, Krüger K, Neubauer AS, Dupont D, Merkesdal S.
    Clin Exp Rheumatol; 2013 Nov; 31(3):400-8. PubMed ID: 23464803
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of TNF inhibitors vs synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a Markov model study based on two longitudinal observational studies.
    Kvamme MK, Lie E, Uhlig T, Moger TA, Kvien TK, Kristiansen IS.
    Rheumatology (Oxford); 2015 Jul; 54(7):1226-35. PubMed ID: 25573840
    [Abstract] [Full Text] [Related]

  • 8. Cost of biologics per treated patient across immune-mediated inflammatory disease indications in a pharmacy benefit management setting: a retrospective cohort study.
    Wu N, Lee YC, Shah N, Harrison DJ.
    Clin Ther; 2014 Aug 01; 36(8):1231-41, 1241.e1-3. PubMed ID: 25062652
    [Abstract] [Full Text] [Related]

  • 9. Cost-effectiveness of early treatment of ACPA-positive rheumatoid arthritis patients with abatacept.
    Neubauer AS, Minartz C, Herrmann KH, Baerwald CGO.
    Clin Exp Rheumatol; 2018 Aug 01; 36(3):448-454. PubMed ID: 29303709
    [Abstract] [Full Text] [Related]

  • 10. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N, Proudfoot C, Fournier M, Chen CI, Kuznik A, Kiss Z, Gal P, Michaud K.
    Adv Ther; 2019 Jun 01; 36(6):1337-1357. PubMed ID: 31004324
    [Abstract] [Full Text] [Related]

  • 11. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
    Stevenson M, Archer R, Tosh J, Simpson E, Everson-Hock E, Stevens J, Hernandez-Alava M, Paisley S, Dickinson K, Scott D, Young A, Wailoo A.
    Health Technol Assess; 2016 Apr 01; 20(35):1-610. PubMed ID: 27140438
    [Abstract] [Full Text] [Related]

  • 12. Remission and low disease activity matrix tools: results in real-world rheumatoid arthritis patients under anti-TNF therapy.
    Ganhão S, Lucas R, Fonseca JE, Santos MJ, Gonçalves DR, Madeira N, Silva C, Dourado E, Freitas R, Rodrigues J, Azevedo S, Rocha TM, Ferreira RM, Garcia S, Fernandes BM, Prata AR, Couto M, Torres RP, Cunha I, Costa L, Bernardes M.
    Acta Reumatol Port; 2020 Apr 01; 45(4):245-252. PubMed ID: 33420771
    [Abstract] [Full Text] [Related]

  • 13. Comparison of the clinical effectiveness of tumour necrosis factor inhibitors and abatacept after insufficient response to tocilizumab in patients with rheumatoid arthritis.
    Akiyama M, Kaneko Y, Kondo H, Takeuchi T.
    Clin Rheumatol; 2016 Nov 01; 35(11):2829-2834. PubMed ID: 26971256
    [Abstract] [Full Text] [Related]

  • 14. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F, Massafra U, Perricone C, Idolazzi L, Giacomelli R, Tirri R, Russo R, Pistone G, Ruscitti P, Parisi S, Sainaghi PP, Cacciapaglia F, Zullo A, Marino V, Migliore A, Valesini G.
    Clin Exp Rheumatol; 2017 Nov 01; 35(1):24-32. PubMed ID: 27974105
    [Abstract] [Full Text] [Related]

  • 15. Comparative effectiveness of first-line biological monotherapy use in rheumatoid arthritis: a retrospective analysis of the RECord-linkage On Rheumatic Diseases study on health care administrative databases.
    Silvagni E, Bortoluzzi A, Carrara G, Zanetti A, Govoni M, Scirè CA.
    BMJ Open; 2018 Sep 11; 8(9):e021447. PubMed ID: 30206082
    [Abstract] [Full Text] [Related]

  • 16. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis.
    Doan QV, Chiou CF, Dubois RW.
    J Manag Care Pharm; 2006 Sep 11; 12(7):555-69. PubMed ID: 16981801
    [Abstract] [Full Text] [Related]

  • 17. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N, Betts KA, Messali AJ, Skup M, Garg V.
    Clin Ther; 2017 Aug 11; 39(8):1618-1627. PubMed ID: 28729087
    [Abstract] [Full Text] [Related]

  • 18. Costs of tumor necrosis factor blockers per treated patient using real-world drug data in a managed care population.
    Schabert VF, Watson C, Joseph GJ, Iversen P, Burudpakdee C, Harrison DJ.
    J Manag Care Pharm; 2013 Oct 11; 19(8):621-30. PubMed ID: 24074008
    [Abstract] [Full Text] [Related]

  • 19. Cost-effectiveness of adalimumab, etanercept, and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis.
    Soini EJ, Hallinen TA, Puolakka K, Vihervaara V, Kauppi MJ.
    J Med Econ; 2012 Oct 11; 15(2):340-51. PubMed ID: 22168785
    [Abstract] [Full Text] [Related]

  • 20. Pharmacoeconomic analysis of biological disease modifying antirheumatic drugs in patients with rheumatoid arthritis based on real-world data from the IORRA observational cohort study in Japan.
    Tanaka E, Inoue E, Yamaguchi R, Shimizu Y, Kobayashi A, Sugimoto N, Hoshi D, Shidara K, Sato E, Seto Y, Nakajima A, Momohara S, Taniguchi A, Yamanaka H.
    Mod Rheumatol; 2017 Mar 11; 27(2):227-236. PubMed ID: 27472516
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.